We thank Yunfeng Fu and colleagues for their important comments on the IFM2017-03 trial1. We provide below the most accurate information available to address their remarks.
[Correspondence] Daratumumab–lenalidomide and the immunosuppressive budget in myeloma – Authors' reply
The Lancet Oncology | | Salomon Manier, Jérôme Lambert, Cyrille Hulin, Margaret Macro, Xavier Leleu, Thierry Facon
Topics: blood-cancer